Join our host, Oliver Gautschi, for an insightful roundtable on evolving targeted therapies in NSCLC. This exciting roundtable brings together renowned experts Jarushka Naidoo and Nicolas Girard to explore current standards and challenges in ALK+ and EGFR+ NSCLC, including optimizing targeted therapy approaches in both early and advanced stages and tackling resistance mechanisms in EGFR-mutated disease. The discussion will also focus on unlocking synergies with chemotherapy, bispecific antibodies, and TKIs, highlighting the latest combination strategies and guidance on managing adverse events. In addition, the panel will examine novel single-agent therapies across different stages of NSCLC. Don’t miss this opportunity to deepen your understanding, engage with experts through interactive case discussions, and discover the future of targeted therapies in NSCLC treatment.